Mode
Text Size
Log in / Sign up

Atherogenic index of plasma shows non-linear association with mortality in diabetic AKI patients

Atherogenic index of plasma shows non-linear association with mortality in diabetic AKI patients
Photo by Logan Voss / Unsplash
Key Takeaway
Consider AIP as a biomarker for mortality risk in diabetic AKI, but note observational limitations.

This retrospective cohort study, conducted at the First Affiliated Hospital of Guangxi Medical University, included 1046 diabetic patients with acute kidney injury. The intervention or exposure was the atherogenic index of plasma (AIP), with comparisons made across quartiles of baseline AIP (Q1, Q2, Q3, Q4). The primary outcome was all-cause death, and secondary outcomes included renal non-recovery, with an average follow-up of 101.13 ± 64.81 days.

Main results showed an all-cause mortality rate of 16.8% and a renal non-recovery rate of 69.4%. AIP had a non-linear association (inverted U-shape) with all-cause death, with a hazard ratio (HR) of 5.427 (95% CI = 2.999-9.821). For renal non-recovery, multivariate analysis indicated a non-linear association (S-shape) with an HR of 2.769 (95% CI = 2.085-3.677). However, competing risk analysis, accounting for death as a competing event, revealed that AIP was not significantly associated with renal non-recovery (HR = 1.126, 95% CI: 0.864–1.467, P = 0.380).

Safety and tolerability data were not reported. Key limitations were not specified in the input, but the study is observational, meaning associations do not imply causation. Practice relevance suggests AIP may serve as a useful biomarker for mortality risk stratification rather than for predicting renal recovery, based on the non-linear associations found.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo explore the correlation between atherogenic index of plasma (AIP) and all-cause death and renal non-recovery in diabetic patients with acute kidney injury (AKI).MethodsA retrospective analysis was conducted on the baseline and follow-up clinical data of diabetic patients with AKI in the First Affiliated Hospital of Guangxi Medical University from April 2010 to April 2025. The baseline AIP is calculated as log10 [TG (mg/dL)/HDL-C(mg/dL)]. Diabetic patients with AKI were divided into Q1, Q2, Q3, and Q4 groups based on the quartiles of baseline AIP. The differences in clinical data among different AIP groups were compared. The predictive value of AIP for all-cause death and non-recovery of renal function in diabetic patients with AKI was evaluated by drawing receiver operating characteristic (ROC) curves. The association between AIP and clinical outcomes in diabetic patients with AKI was analyzed using multivariable Cox regression and restricted cubic spline (RCS) regression.ResultA total of 1046 diabetic patients with AKI were enrolled, with a male to female ratio of 2:1. The average age was 62.40 ± 13.57 years. The average follow-up period was 101.13 ± 64.81 days. The all-cause mortality was 16.8%, and the rate of lack of renal recovery was 69.4%. The area under ROC curves for AIP in predicting all-cause death and lack of renal recovery in diabetic AKI patients were 0.805 and 0.782, respectively. The multivariate Cox and RCS regression analysis showed that after adjusting for confounding factors, the AIP level were non-linear associated with risk of all-cause death (HR = 5.427, 95%CI=2.999-9.821, inverted U-shape) and non-recovery of renal function (HR = 2.769, 95% CI = 2.085-3.677, S-shape) in diabetic patients with AKI. However, competing risk analysis revealed that after accounting for death as a competing event, AIP was no longer significantly associated with renal non-recovery (HR = 1.126, 95% CI: 0.864–1.467, P = 0.380).ConclusionAIP is non-linearly associated with all-cause death in diabetic patients with AKI, and may serve as a useful biomarker for mortality risk stratification rather than for predicting renal recovery.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.